The validation set comprised three APP-mutation CAA cases (Boston criteria), one CADASIL-like case, nine non-AD gene carriers (e.g., VCP, PDGFRB), and four additional randomly selected carriers. This evidence concerns the gene APP and Alzheimer disease.